Boston, MA – March 21, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced plans to present at two upcoming medicinal chemistry conferences.
- 7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets held March 27-28 in Cambridge, UK
- Binding Kinetics and Mechanistic PK/PD Modeling in Early Drug Discovery Conference held March 27-28in Cambridge, UK
7th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets Conference
Presentation Details
Title: Identification of THIK-1 as a therapeutic target for neuroinflammatory diseases: Discovery and characterisation of a selective THIK-1 blocker
Overview: The NETSseq platform can identify unexplored and druggable microglia targets, exemplified by THIK-1, as potential therapies for neurodegenerative diseases. The discovery of a THIK-1 inhibitor, C101248, and its pharmacological profile, as well as its effect in microglia, is explored.
Presenter: Anna Rowland, PhD
Session Date and Time: March 27, 2023, 1:30-2:45pm
Binding Kinetics and Mechanistic PK/PD Modelingin Early Drug Discovery Conference
Poster Details
Title :Analysis of the Initial Velocity of Calcium Signalling and β-Arrestin Recruitment at GPR55 with Different Activators ShowsUnique Signalling Profiles
Overview: Three proprietary small molecule activators of GPR55 display unique signalling profiles when measuring the initial velocity of calcium and β-arrestin pathway activation.
Presenter: Philip Pickford
Poster Number: 10
About Cerevance
Cerevanceis a private pharmaceutical company with a focus on CNS disorders. CVN424,Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergiccompound acting on a novel target (GPR6), that demonstrated significant andclinically meaningful efficacy in a 136-patient Phase 2 study in patients withParkinson’s disease. The company uses its proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq)platform to identify highly selectively expressed, novel target proteins thatare either specific to certain brain circuits or are over- or under-expressedin diseased brains. Partnering with over 25 brain banks and evaluating anexpanding collection of more than 12,000 human post-mortem brain tissuesamples, Cerevance is advancing a robust pipeline of targeted treatments forpatients with neurodegenerative diseases, including Parkinson’s disease,Amyotrophic Lateral Sclerosis and Alzheimer’s disease. For additional information, please visit www.cerevance.com.
Contacts
Cerevance:
Johnna Simoes, ir@cerevance.com
Media:
Andrew Mielach, amielach@lifescicomms.com, +1-646-876-5868
